Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>Orforglipron

Orforglipron

Orforglipron Structure
Orforglipron structure
CAS No.
2212020-52-3
Chemical Name:
Orforglipron
Synonyms
LY3502970;Orforglipron（LY3502970）;1,2,4-Oxadiazol-5(2H)-one,3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazChemicalbookol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H;3-((1S,2S)-1-(5-((S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl;OWL 833;Ogerlon;Oglegron;Orforglipron;0rforglipron;LY3502970 (Orforglipron)
CBNumber:
CB45419742
Molecular Formula:
C48H48F2N10O5
Molecular Weight:
882.97
MDL Number:
MOL File:
2212020-52-3.mol
MSDS File:
SDS
TDS File:
TDS
Last updated:2026-07-29 08:43:58
Product description Number Pack Size Price
Orforglipron ≥95% 39741 1mg $61
Orforglipron ≥95% 39741 5mg $167
Orforglipron ≥95% 39741 10mg $303
Orforglipron MND02052 1mg $550
Orforglipron MND02052 5mg $1375
Request For Quotation

Orforglipron Properties

Density 1.50±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : 125 mg/mL (141.57 mM)
form Solid
pka 7.33±0.20(Predicted)
color Off-white to light yellow
InChIKey USUWIEBBBWHKNI-BBGRWQLENA-N
FDA UNII 7ZW40D021M

Orforglipron price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 39741 Orforglipron ≥95% 2212020-52-3 1mg $61 2026-04-30 Buy
Cayman Chemical 39741 Orforglipron ≥95% 2212020-52-3 5mg $167 2026-04-30 Buy
Cayman Chemical 39741 Orforglipron ≥95% 2212020-52-3 10mg $303 2026-04-30 Buy
Biosynth MND02052 Orforglipron 2212020-52-3 1mg $550 2026-06-04 Buy
Biosynth MND02052 Orforglipron 2212020-52-3 5mg $1375 2026-06-04 Buy
Product number Packaging Price Buy
39741 1mg $61 Buy
39741 5mg $167 Buy
39741 10mg $303 Buy
MND02052 1mg $550 Buy
MND02052 5mg $1375 Buy

Orforglipron Chemical Properties,Uses,Production

Description

Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is  GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.

History

Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.

Uses

Orforglipron is a non-peptide oral glucagon-like peptide-1 receptor agonist (GLP-1RA) widely used in the management of type 2 diabetes mellitus (T2DM) and obesity. In T2DM patients, the drug reduces glycated haemoglobin (HbA1c) by up to 2.10%, facilitates weight loss of up to 10.1 kilograms, and reduces waist circumference by up to 8.7 centimetres. Studies in overweight or obese populations indicate weight loss of up to 13.0 kilograms. Adverse reactions include mild to moderate vomiting and nausea, particularly common following high-dose therapy or rapid dose escalation. Consequently, it should be used cautiously under medical supervision.

Uses

Glucagon-like peptide-1 (GLP-1) agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat type 2 diabetes mellitus and, in some cases, obesity.

in vivo

Orforglipron (0.94-4.8 nM in plasma concentration, i.v., or 0.05-0.1 mg/mL, i.g. for 5 days) suppresses food intake in a dose-dependent manner, promotes insulin secretion and decreases blood glucose in cynomolgus monkey model[1].
Orforglipron (0.05-1.35 mg/kg, i.g.) reaches Cmax 2 hours after administration at all doses, exhibits proportional ratio of increase in plasma drug exposure to dose increase, indicates a dose-dependent absorption in the gastrointestinal tract[1].

Pharmacokinetic Analysis of Orforglipron in cynomolgus monkey [1]

routeDose (mg/kg)Tmax (h)Cmax (ng/mL)AUC0-24h (ng·h/mL)
i.g.0.052.04.7823.7
i.g.0.152.020.7135
i.g.0.452.032.0208
i.g.1.352.01481040
Animal Model:cynomolgus monkey model[1]
Dosage:0.9-4.8 nM; 0.05-0.1 mg/mL
Administration:continuous i.v. administration for 30 minutes until a plasma concentration of 0.9-4.8 nM at steady state;
i.g. for 5 days with dose of 0.05-0.1 mg/mL
Result:Increased insulin secretion and decreased plasma-glucose. Suppressed food intake in a dose-dependent manner.

Research

Orforglipron is a synthetic, orally bioavailable, non-peptide small-molecule GLP-1 receptor agonist that acts as a biased, partial allosteric agonist[1][2][3]. In clinical trials including the Phase 3 ATTAIN-1 study, Orforglipron produced dose-dependent improvements in modifiable atherosclerotic cardiovascular disease risk factors, such as body weight, HbA1c, systolic blood pressure, and lipid profiles, demonstrating sustained weight reduction in non-diabetic obesity over 72 weeks[3]. Treatment discontinuation due to any adverse event was significantly higher with Orforglipron than with placebo across Phase 2 and Phase 3 trials[3].

References

[1] Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026). Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. International Journal of Molecular Sciences, 27 3. https://doi.org/10.3390/ijms27031409
[2] Ramadurgum, P., Shah, J., Shah, E., & Palmer, B. F. (2026). Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist. Frontiers in Pharmacology, 17, 1917800. https://doi.org/10.3389/fphar.2026.1917800
[3] Alper, A., Peleg, G., Fagin, A., Shah, P., Chowdhury, I., Gonzales, A., & Faillace, R. (2026). Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review. Cardiovascular Diabetology. Endocrinology Reports, 12 1, 9. https://doi.org/10.1186/s40842-025-00270-4

Orforglipron Preparation Products And Raw materials

Raw materials

Preparation Products

Orforglipron Suppliers

Global( 278)Suppliers
Supplier Tel Email Country ProdList Advantage
Rongchuang International 		+86-13175533356 +86-13175533356 kevin@rongchuangintl.com China 256 58
Tianjin Aobos Cosmetics Co., Ltd 		+undefined+86-85246707735 monikahi777@gmail.com China 11 58
Guangzhou Weiaokang Pharmaceutical Technology Co., Ltd
+86-13424074264 pengguizi@cti-cert.com China 156 58
Xi an Biohorlden Industry Trade Co Ltd
+86-13636819721 sales@horlden.com China 332 58
Jinan Jianfeng Chemical Co., Ltd
+86-0531-88110457 +86-15562555968 info@pharmachemm.com China 302 58
Chongqing jooe co., ltd
+86-15223382610 info@jooe.com China 15967 58
LIDE PHARMACEUTICALS LIMITED
+852-55945652 export@lidepharma.com China 302 58
RongNa Biotechnology Co.,Ltd
+86-86-13583358881 +8618560316533 Brad@rongnabiotech.com China 3371 58
Zibo Hangyu Biotechnology Development Co., Ltd
+86-0533-2185556 +86-15965530500 nickzhang@hangyubiotech.com China 9935 58
NANJING YINGWEN BIOTECHNOLOGY CO LTD
+86-13382787392 sales@aeechem.com China 10002 58
Supplier Advantage
Rongchuang International 		58
Tianjin Aobos Cosmetics Co., Ltd 		58
Guangzhou Weiaokang Pharmaceutical Technology Co., Ltd
58
Xi an Biohorlden Industry Trade Co Ltd
58
Jinan Jianfeng Chemical Co., Ltd
58
Chongqing jooe co., ltd
58
LIDE PHARMACEUTICALS LIMITED
58
RongNa Biotechnology Co.,Ltd
58
Zibo Hangyu Biotechnology Development Co., Ltd
58
NANJING YINGWEN BIOTECHNOLOGY CO LTD
58

View Lastest Price from Orforglipron manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
orforglipron pictures 2026-08-14 orforglipron
2212020-52-3
 $1.00 300g 99.8% 20 TONS .GZ HONESTCHEM CO.,LTD
Orforglipron（LY3502970） pictures 2026-08-14 Orforglipron（LY3502970）
2212020-52-3
 $10.00 1ASSAYS 99% 1 ton RongNa Biotechnology Co.,Ltd
Orforglipron pictures 2026-08-14 Orforglipron
2212020-52-3
 $10.00 1mg tablets 99% HIGH PURITY 5000KG Shanghai Zheng Peptide Plastic Co., Ltd.
  • Orforglipron pictures
  • Orforglipron
    2212020-52-3
  • $10.00
  • 99% HIGH PURITY
  • Shanghai Zheng Peptide Plastic Co., Ltd.

Orforglipron Spectrum

Orforglipron(2212020-52-3)1HNMR

2212020-52-3(Orforglipron)Related Search:

(S,E)-1-(4-fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1-(2-hydroxyvinyl)urea \\ 5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclopropyl]-1H-indole-2-carboxylic Acid 1H-Indole-2-carboxamide, N-methyl-N-phenyl-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]- (R)-1-(4-fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1,3-dihydro-2H-imidazol-2-one
3-((1S,2R)-1-(5-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((R)-3- (3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1Himidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7- tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2- methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one Ly3502970

1of2

1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy... GLP-1 receptor agonist 1 USP/EP/BP Orforglipron LY3502970 (Orforglipron) 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one OWL 833 LY3502970|||GLP-1 receptor agonist 1 1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]- Orforglipron, 10 mM in DMSO Research Grade Orforglipron 1,2,4-Oxadiazol-5(2H)-one,3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazChemicalbookol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy 0rforglipron 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-1,2,4-Oxadiazol-5(2H)-one Ogerlon Orforglipron，PhEur/USP(DMF) Orforglipron raw materials,Peptide customization Orforglipron/GLP-1 receptor agonist 1 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahyd 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-1,2,4-oxadiazolidin-5-one 3-((1S,2S)-1-(5-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-... 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-imidazole-5-yl)-2-oxy-2,3-dihydro-1H-imidazole-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyridineazolebenzo[4,3-c]pyridine-5-carbonyl)-1H-indole-1-yl)-2-methylcyclopropyl-4,5,6,7-diazole-5(4H)-one Oglegron (1R,2R)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-(3-(4-fluoro-1-methyl-2,3-dihydro-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1 1,2,4-Oxadiazol-5(2H)-one,3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazChemicalbookol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H 3-((1S,2S)-1-(5-((S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl LY3502970 Orforglipron（LY3502970） 3-[(1S,2S)-1-[2-[[(4S)-2-(4-Fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-1,2,4-oxadiazol-5(2H)-one (ACI) 2212020-52-3 2720883-00-0 C48H48F2N10O5 1 ADVANCED INT. API